One thing that should have been funded (or still should be funded) is a massive testing program.
Nobel Prize winning economist Paul Romer has a workable plan: https://roadmap.paulromer.net/paulromer-roadmap-report.pdf
Nobel Prize winning economist Paul Romer has a workable plan: https://roadmap.paulromer.net/paulromer-roadmap-report.pdf
To control this pandemic, and any future pandemic, the U.S. should make the investment necessary to test people every two weeks, which would mean 25 million tests per day on an ongoing basis. It should also have a surge capacity of twice this amount, which would allow us to test every Amer- ican every week if needed. At the moment, the U.S. is testing around 150,000 people daily, and to make matters worse, we are testing the wrong people. Instead of testing those with symptoms, our urgent priority should be to test people who might be asymptomatic spreaders of the virus.
Achieving this level of testing is difficult, but entirely feasible. The sooner we focus our efforts towards the necessary steps to making testing ubiquitous, the sooner we can reopen the economy and restore people’s confidence in the future. It is the only path to certainty that makes it safe to return to work, safe to visit your grandparents, safe to put your child back in school, and a myriad other things that have become dilemmas during the pandemic.
At scale, a reasonable estimate would be a $10 cost per test for labs. 20 million tests per day translates into about $73 billion per year. Along with other costs for infrastructure, training, and production of supplies, I estimate the government will need to allocate $100 billion to the development of a testing strategy. I urge Congress to include the $100 billion in the Phase 4 coronavirus stimulus bill to generate a revenue stream for labs as soon as possible. The market cannot independently solve this problem. The need for a new revenue stream that creates neces- sary incentives for labs to innovate at the scale possible is inescapable.
For each month of lockdown, the U.S. economy suffers a loss of $500 billion from lost output that month and lost capacity to produce in the future. Lifting the lockdown without a clear containment strategy will have relatively little financial impact due to continued fear and uncertainty (we may cut the loss to $400 billion a month) and will undoubtedly carry extraordinary human cost. A temporary relaxation of lockdown will offer little economic benefit because it won’t give consumers or firms the necessary confidence to plan and invest.
The economic argument for investing in an approach we know will provide certainty and safety is undeniable. A $100 billion annual investment in testing until all Americans have been vaccinated would pay for itself many times over, and it would provide the necessary revenue stream for labs to rapidly expand testing capacity.
Last edited: